Parkinsonism clinical trials at UCSF
1 research study open to eligible people
Parkinsonism is a condition with symptoms like tremors and slow movement. UCSF is studying if a single dose of zoledronic acid can prevent bone fractures in people with parkinsonism. This study is done at home and compares the drug to a placebo.
Parkinson's and Zoledronic Acid
open to eligible people ages 60 years and up
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.
San Francisco, California and other locations
Last updated: